Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...
COMP360 is the first classic psychedelic 1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profile In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results